Christina Caon

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. doi request reprint Maximising therapeutic outcomes in patients failing on current therapy
    Christina Caon
    Multiple Sclerosis Center, Department of Neurology, Wayne State University, Detroit, MI, USA
    J Neurol Sci 277:S33-6. 2009
  2. ncbi request reprint Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data
    Christina Caon
    Multiple Sclerosis Center at Wayne State University School of Medicine, Detroit, MI, USA
    J Neurosci Nurs 42:S5-9. 2010
  3. doi request reprint Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis
    Omar Khan
    Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neuroimaging 18:314-9. 2008
  4. doi request reprint Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    Omar Khan
    MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Neurol Sci 312:7-12. 2012
  5. ncbi request reprint Acute transverse myelitis with normal brain MRI : long-term risk of MS
    Jui Perumal
    Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    J Neurol 255:89-93. 2008
  6. doi request reprint Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
    Aaron Boster
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Arch Neurol 66:593-9. 2009
  7. ncbi request reprint Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Mult Scler 11:646-51. 2005
  8. ncbi request reprint Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
    CNS Drugs 16:563-78. 2002
  9. doi request reprint Pediatric-onset multiple sclerosis in African-American black and European-origin white patients
    Aaron L Boster
    Department of Neurology, The Ohio State University, Columbus, Ohio, USA
    Pediatr Neurol 40:31-3. 2009

Collaborators

  • Omar Khan
  • Jiani Hu
  • Kenneth L Tyler
  • Carol Saunders
  • Jennifer Smrtka
  • Aaron Boster
  • Aaron L Boster
  • Fen Bao
  • Alexandros Tselis
  • Imad Zak
  • Jui Perumal
  • Jai S Perumal
  • Stephanie Hreha
  • Jai Perumal
  • Christina F Endress
  • Scott Millis
  • Stephanie A Hreha
  • Christina Endress
  • Jose Vazquez
  • Ramya Penmesta
  • Joseph R Berger
  • Michael K Racke
  • Rana Zabad
  • Robert Lisak
  • Zahid Latif
  • Megan MacKenzie

Detail Information

Publications9

  1. doi request reprint Maximising therapeutic outcomes in patients failing on current therapy
    Christina Caon
    Multiple Sclerosis Center, Department of Neurology, Wayne State University, Detroit, MI, USA
    J Neurol Sci 277:S33-6. 2009
    ..Formal switching algorithms need to be developed in order to ensure that all patients who could benefit from such an approach are managed in a timely and optimal manner...
  2. ncbi request reprint Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data
    Christina Caon
    Multiple Sclerosis Center at Wayne State University School of Medicine, Detroit, MI, USA
    J Neurosci Nurs 42:S5-9. 2010
    ..Nursing interventions that can improve adherence, including telephone counseling and motivational interview techniques, are also addressed...
  3. doi request reprint Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis
    Omar Khan
    Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neuroimaging 18:314-9. 2008
    ..These data support the long-term effect of GA on maintaining axonal metabolic function and protection from sublethal injury as well as the feasibility of employing brain (1)H-MRS in long-term investigative studies in MS...
  4. doi request reprint Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    Omar Khan
    MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Neurol Sci 312:7-12. 2012
    ..To compare the long-term effect of disease-modifying therapies (DMT) on brain volume loss in relapsing-remitting MS (RRMS) patients...
  5. ncbi request reprint Acute transverse myelitis with normal brain MRI : long-term risk of MS
    Jui Perumal
    Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    J Neurol 255:89-93. 2008
    ..To investigate the long-term risk of developing MS in patients presenting with acute transverse myelitis (ATM) and normal brain MRI scans at onset...
  6. doi request reprint Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
    Aaron Boster
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Arch Neurol 66:593-9. 2009
    ..To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS)...
  7. ncbi request reprint Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Mult Scler 11:646-51. 2005
    ..These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA...
  8. ncbi request reprint Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
    CNS Drugs 16:563-78. 2002
    ..In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients...
  9. doi request reprint Pediatric-onset multiple sclerosis in African-American black and European-origin white patients
    Aaron L Boster
    Department of Neurology, The Ohio State University, Columbus, Ohio, USA
    Pediatr Neurol 40:31-3. 2009
    ..50; P < 0.001). These findings are consistent with data suggesting a more aggressive disease phenotype among African-American blacks with adult-onset multiple sclerosis. Larger multicenter studies are warranted to confirm the findings...